What is cagrilintide, and how does the amylin analog work for weight loss?

The short answer

Cagrilintide is Novo Nordisk's long-acting amylin analog — a once-weekly injectable that mimics the satiety hormone amylin to reduce appetite and body weight. In a Phase 2 trial, cagrilintide alone produced roughly 11% weight loss over 26 weeks, and it's best known as the amylin half of CagriSema (cagrilintide + semaglutide). It's investigational and not approved as a standalone drug.

Evidence tier: Tier 1 for the Phase 2 weight-loss data; Tier 2 for cross-trial comparisons. Educational content, not medical advice.

The key points:

• Amylin analog — a different appetite pathway from GLP-1
• ~11% weight loss alone in Phase 2 at the top dose over 26 weeks
• The amylin half of CagriSema (with semaglutide)
• Investigational — not approved as a standalone weight-loss drug

For the combination, see the CagriSema deep-dive.

What is cagrilintide?

Evidence tier: 2 — established pharmacology.

Cagrilintide (development code AM833) is a long-acting amylin analog from Novo Nordisk, given as a once-weekly subcutaneous injection. Amylin is a hormone your pancreas co-secretes with insulin from the same beta cells; it promotes satiety, slows gastric emptying, and reduces food intake — a genuinely different appetite lever from the GLP-1 pathway that semaglutide and tirzepatide use. Cagrilintide is an acylated, non-selective amylin-receptor agonist engineered for a long duration of action so it can be dosed weekly rather than needing the frequent dosing native amylin would require.

Why does amylin matter as a target? For years, obesity drug development centered on the incretin hormones (GLP-1, GIP) and glucagon. Amylin is the emerging "next pillar" — a separate satiety signal that can be combined with GLP-1 for additive appetite suppression, which is exactly the logic behind CagriSema. So cagrilintide is interesting both as a standalone agent and, more prominently, as a component that adds a second, complementary mechanism on top of GLP-1. Understanding what it does on its own is the foundation for understanding the combinations built on it.

How much weight loss does cagrilintide cause?

Evidence tier: 1 — Phase 2 randomized trial.

The core evidence comes from a Phase 2, dose-finding, randomized, double-blind trial published in The Lancet, which tested once-weekly cagrilintide (0.3 to 4.5 mg) against once-daily liraglutide 3.0 mg and placebo in people with overweight or obesity over 26 weeks (Lau et al. 2021). At the top 4.5 mg dose, cagrilintide produced roughly 10–11% body-weight loss, numerically ahead of liraglutide (a then-standard GLP-1 comparator) and well ahead of placebo, and it was generally well tolerated — mainly gastrointestinal effects (nausea) and injection-site reactions, consistent with the class.

That's a solid result for a monotherapy: ~11% from an amylin analog alone, beating an established GLP-1 drug in the same trial, is a genuine proof-of-concept that amylin is a powerful standalone appetite target. The usual caveats apply — this is Phase 2, 26 weeks, dose-finding — but the signal is clear and clinically meaningful. It established cagrilintide as a real weight-loss agent in its own right, which is what justified building the higher-profile combination around it. The honest framing: cagrilintide works as a standalone in Phase 2; whether it's developed and approved as a monotherapy, versus mainly as a combination component, is a separate commercial and clinical question.

Cagrilintide and CagriSema — what's the relationship?

Evidence tier: 1–2 — combination trial data.

Cagrilintide's biggest role is as the amylin half of CagriSema — cagrilintide combined with semaglutide (the GLP-1 in Wegovy/Ozempic). The rationale is mechanistic addition: amylin satiety plus GLP-1 satiety, two different pathways pushing appetite down together, aiming for greater weight loss than either alone. Cagrilintide has also been studied combined with semaglutide in type 2 diabetes in a Phase 2 trial (Lancet 2023), and the CagriSema obesity program has drawn major attention as a potential top-tier weight-loss therapy.

So when people research "cagrilintide," they're often really interested in CagriSema — and it's worth being clear which they mean. Cagrilintide alone is the ~11% Phase 2 monotherapy; CagriSema is the combination that pairs it with semaglutide for potentially larger effect (with its own nuances and trial results, covered in the CagriSema deep-dive). There's also a broader trend here: amylin is being pursued across the industry, including in unimolecular GLP-1/amylin agents like amycretin, which fold both actions into a single molecule rather than combining two drugs. Cagrilintide is the compound that most clearly established amylin as a serious obesity target.

How does amylin compare to the other obesity mechanisms?

Evidence tier: 2 — mechanistic and cross-trial context.

The obesity-drug landscape now spans several hormone pathways: GLP-1 (semaglutide), GLP-1 + GIP (tirzepatide, VK2735), GLP-1 + glucagon (survodutide, pemvidutide), GLP-1 + GIP + glucagon (retatrutide), and now amylin — solo (cagrilintide) or combined with GLP-1 (CagriSema, amycretin). Amylin's appeal is that it's a distinct satiety mechanism, so it stacks additively with GLP-1 rather than overlapping, and it may help preserve the response to weight loss over time (amylin as a future obesity treatment, review; next-gen multi-agonists overview).

The standard caveat holds: comparing cagrilintide's ~11% to figures from separate tirzepatide or retatrutide trials is cross-trial, not head-to-head, so it's suggestive rather than definitive. What's fair to say is that cagrilintide proved amylin is a legitimately effective standalone lever, and that its main strategic value is as a building block for combinations that exploit multiple pathways at once. In a field increasingly defined by "which hormones can we safely stack," amylin — via cagrilintide — is one of the most important additions, which is why nearly every major player now has an amylin program.

It's worth noting cagrilintide isn't the only amylin drug in development. Competitors are advancing their own amylin analogs — for example Zealand Pharma's petrelintide — as both monotherapies and GLP-1 combinations, and the unimolecular GLP-1/amylin agents like amycretin fold both actions into one molecule. That competitive rush is itself a signal: it reflects a broad industry bet that amylin is a durable, additive mechanism rather than a one-off. Whether cagrilintide specifically becomes a marketed standalone, or remains primarily the amylin engine inside CagriSema, its scientific contribution — validating amylin as an obesity target worth building a whole class around — is already established. For a prospective patient that distinction matters less than the timeline: any of these is still moving through development, not available to source safely today.

What's the current status and how do you get it?

Evidence tier: 1–2 — regulatory status.

The essential fact: cagrilintide is investigational and not approved as a standalone weight-loss drug. Its most advanced role is within the CagriSema program, and its monotherapy data are Phase 2. So you cannot get cagrilintide by prescription as a solo therapy, and anything sold online as "cagrilintide" is gray-market and unverified — an unapproved research peptide with the authenticity, purity, dosing, and contamination risks that apply to any self-sourced injectable (spotting counterfeit peptides).

For anyone whose actual goal is weight loss, the practical takeaway is that cagrilintide is a promising investigational compound to watch — especially as the amylin field matures and as CagriSema moves through late-stage development — but not something to source and self-administer today. The proven, available options remain the approved GLP-1 therapies used under medical supervision, plus the fundamentals. Cagrilintide's significance is what it represents for the future of obesity treatment: a validated new mechanism that expands the toolkit beyond the incretin hormones.

Limitations

This is educational content, not medical advice.

• Monotherapy data are Phase 2 (26 weeks, dose-finding) — promising, but not confirmatory.
• Cross-trial comparisons aren't head-to-head — don't directly rank cagrilintide vs tirzepatide/retatrutide numbers.
• Not approved as a standalone drug — its main development is within CagriSema.
• Online "cagrilintide" is gray-market and unverified — not the trial product.
• Amylin's long-term benefits and safety are still being established in larger trials.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Cagrilintide is Novo Nordisk's long-acting amylin analog — a once-weekly injectable that uses a satiety pathway distinct from GLP-1, and in Phase 2 it delivered roughly 11% weight loss on its own, beating an established GLP-1 comparator. Its biggest role, though, is as the amylin half of CagriSema, where it's paired with semaglutide to stack two appetite mechanisms. It's investigational and not approved as a standalone, so anything sold as "cagrilintide" online is gray-market and unverified. Its real importance is strategic: cagrilintide established amylin as a serious, effective new lever in obesity pharmacology — one that nearly every major drugmaker is now building on. Watch the development; don't source the gray-market version.

Related on this site

• CagriSema deep-dive
• Amycretin (GLP-1/amylin) explained
• Next-gen multi-agonists overview
• GLP-1 complete guide
• Spotting counterfeit peptides
• Our evidence-tier framework

References

• Lau DCW, et al. 2021. Once-weekly cagrilintide for weight management in people with overweight and obesity: a dose-finding phase 2 trial. Lancet 398(10317):2160–2172. PMID 34798060 — cagrilintide monotherapy efficacy.
• Enebo LB, et al. 2023. Cagrilintide plus semaglutide in type 2 diabetes: a phase 2 trial. Lancet. doi:10.1016/S0140-6736(23)01163-7 — cagrilintide + semaglutide combination.
• Amylin as a future obesity treatment (review). PMC. PMC8735818 — amylin biology and therapeutic rationale.